Proteomic aging clocks go to trial
Nature Biotechnology, Published online: 13 October 2026; doi:10.1038/s41587-026-03361-4 Six proteomic aging clocks are deployed in a clinical trial for the first time, revealing more about the clocks than about the drug.
Review the primary source, validate the main result, and establish whether any listed-company transmission is direct.
Classification pending.
The full methodology, effect size, and limitations still require analyst review.
Company impact remains unverified until a direct economic transmission is established.